We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Overall prescription drug sales in the U.S. grew 11.5 percent to $216.4 billion last year despite challenges from new OTC products, concerns about hormone replacement therapies and the reimportation of drugs from Canada, according to IMS Health.
The FDA has shut down four websites it claims sold bogus transdermal contraceptive patches containing no active ingredient in its ongoing enforcement efforts against drug counterfeiters, the agency said Feb. 12.
The average annual percentage growth in the amount Americans spend on prescription drugs is expected to continue to decline over the next decade for a variety of reasons, including a decrease in the number of new drugs and in direct-to-consumer advertising, according to a report released last week by the Centers for Medicare & Medicaid Services (CMS).
Hoping to discourage other states from following Pennsylvania’s lead, generic heavyweight Mylan Laboratories has dropped out of the state’s drug discount program for seniors, arguing the newly required 14 percent rebate on generic drugs is too high.
Drugmakers' anticounterfeiting efforts may be strengthened by new guidelines issued by the Health Industry Group Purchasing Association (HIGPA), a trade group representing 175 healthcare purchasing and supply chain organizations.
The average annual percentage growth in the amount Americans spend on Rx drugs is expected to continue to decline over the next decade, according to a report released yesterday by the Centers for Medicare & Medicaid Services (CMS).
With more insurance plans adopting multitiered drug copays, the widening spread between the lowest-priced generic and the highest-priced nonpreferred brand is boosting the fortunes of generic firms, industry observers say.
Pfizer’s new combination drug Caduet, which treats cholesterol and high blood pressure, presents both challenges and opportunities for generic firms, analysts say.
Generic drugmaker Barr Pharmaceuticals last week reported a 79 percent increase in revenue during the last three months of 2003 compared to the year before — a result that topped other generic firms’ earnings results. Among the generic drugmakers recently reporting financials for the period ending Dec. 31, 2003, were the following: